Suzuki Joji, Ellison Tatyana V, Connery Hilary S, Surber Charles, Renner John A
Brigham and Women's Hospital, Boston, MA, USA.
Kaiser Permanente Southern California, Ontario, CA, USA.
Acad Psychiatry. 2016 Jun;40(3):498-502. doi: 10.1007/s40596-015-0313-1. Epub 2015 May 28.
Psychiatrists are well suited to provide office-based opioid treatment (OBOT), but the extent to which psychiatry residents are exposed to buprenorphine training and OBOT during residency remains unknown.
Psychiatry residency programs in the USA were recruited to complete a survey.
Forty-one programs were included in the analysis for a response rate of 23.7 %. In total, 75.6 % of the programs currently offered buprenorphine waiver training and 78.1 % provided opportunities to treat opioid dependence with buprenorphine under supervision. Programs generally not only reported favorable beliefs about OBOT and buprenorphine waiver training but also reported numerous barriers.
The majority of psychiatry residency training programs responding to this survey offer buprenorphine waiver training and opportunities to treat opioid-dependent patients, but numerous barriers continue to be cited. More research is needed to understand the role residency training plays in impacting future practice of psychiatrists.
精神科医生非常适合提供基于办公室的阿片类药物治疗（OBOT），但精神科住院医师在住院期间接受丁丙诺啡培训和OBOT的程度仍不清楚。
招募美国的精神科住院医师培训项目来完成一项调查。
41个项目被纳入分析，回复率为23.7%。总体而言，75.6%的项目目前提供丁丙诺啡豁免培训，78.1%的项目提供在监督下用丁丙诺啡治疗阿片类药物依赖的机会。项目普遍不仅报告了对OBOT和丁丙诺啡豁免培训的积极看法，还报告了许多障碍。
参与本次调查的大多数精神科住院医师培训项目提供丁丙诺啡豁免培训和治疗阿片类药物依赖患者的机会，但仍有许多障碍被提及。需要更多研究来了解住院医师培训在影响精神科医生未来实践中所起的作用。
Zotero 插件